The potential for aclidinium bromide, a new anticholinergic, in the management of chronic obstructive pulmonary disease

Therapeutic Advances in Respiratory Disease

Volumn 6, Issue 6, 2012, Pages 345-361

  Maltais, François ^a   Milot, Julie ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

aclidinium bromide; bronchodilation; chronic obstructive pulmonary disease (COPD); COPD symptoms; long acting muscarinic antagonist (LAMA); lung function

Indexed keywords

ACLIDINIUM BROMIDE; ANTIBIOTIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; FORMOTEROL; IPRATROPIUM BROMIDE; LONG ACTING DRUG; MOXIFLOXACIN; MUSCARINIC RECEPTOR BLOCKING AGENT; PREDNISONE; SALBUTAMOL; SALMETEROL; THEOPHYLLINE; TIOTROPIUM BROMIDE;

ANTICHOLINERGIC EFFECT; ARTHRALGIA; BACKACHE; BRONCHITIS; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONSTIPATION; COUGHING; DIARRHEA; DISEASE EXACERBATION; DISEASE SEVERITY; DIZZINESS; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG INDICATION; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SELECTIVITY; DYSPEPSIA; DYSPNEA; FATIGUE; FORCED EXPIRATORY VOLUME; HEADACHE; HUMAN; HYPERTENSION; INFLUENZA; INSOMNIA; LUNG FUNCTION TEST; NAUSEA; NONHUMAN; OROPHARYNX PAIN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POWDER INHALER; PRIORITY JOURNAL; REVIEW; RHINITIS; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE DRUG DOSE; SYMPTOMATOLOGY; TOOTH PAIN; TREATMENT OUTCOME; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; XEROSTOMIA;

ANIMALS; BRONCHODILATOR AGENTS; DELAYED-ACTION PREPARATIONS; DRY POWDER INHALERS; HUMANS; MUSCARINIC ANTAGONISTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECEPTOR, MUSCARINIC M3; SCOPOLAMINE DERIVATIVES; TROPANES;

EID: 84870198867     PISSN: 17534658     EISSN: 17534666     Source Type: Journal    
DOI: 10.1177/1753465812463626     Document Type: Review

References (69)

1. Abrams P. Andersson K. Buccafusco J. Chapple C. de Groat W. Fryer A. (2006) Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol 148: 565–578.
2. Agusti A. Calverley P. Celli B. Coxson H. Edwards L. Lomas D. (2010) Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res 11: 122.
3. Agusti A. Hedner J. Marin J. Barbe F. Cazzola M. Rennard S. (2011a) Night-time symptoms: a forgotten dimension of COPD. Eur Respir Rev 20: 183–194.
4. Agusti A. Jones P. Bateman E. Singh D. Lamarca R. de Miquel G. (2011b) Improvement in symptoms and rescue medication use with aclidinium bromide in patients with chronic obstructive pulmonary disease: results from ATTAIN [poster]. In: Proceedings of the European Respiratory Society Annual Congress, 24–28 September 2011, Amsterdam, the Netherlands.
5. Alberti J. Martinet A. Sentellas S. Salva M. (2010) Identification of the human enzymes responsible for the enzymatic hydrolysis of aclidinium bromide. Drug Metab Dispos 38: 1202–1210.
6. Alberti J. Sentellas S. Salva M. (2011) In vitro liver metabolism of aclidinium bromide in preclinical animal species and humans: identification of the human enzymes involved in its oxidative metabolism. Biochem Pharmacol 81: 761–776.
7. Anzueto A. Ferguson G. Feldman G. Chinsky K. Seibert A. Emmett A. (2009) Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes. COPD 6: 320–329.
8. Barnes P. (2004) The role of anticholinergics in chronic obstructive pulmonary disease. Am J Med 117(Suppl. 12A): 24S–32S.
9. Bateman E. Singh D. Jones P. Agusti A. Lamarca R. de Miquel G. (2011) The ATTAIN study: safety and tolerability of aclidinium bromide in chronic obstructive pulmonary disease [poster]. In: Proceedings of the European Respiratory Society Annual Congress, 24–28 September 2011, Amsterdam, the Netherlands.
10. Beier J. Mroz R. Singh D. Sliwinski P. Ribera A. Garcia Gil E. (2010) A phase II, three-period, cross-over study evaluating the impact of time of dosing of aclidinium bromide on the bronchodilator response in patients with moderate to severe COPD [oral presentation]. In: Proceedings of the Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin, 17–20 March 2010, Hannover, Germany.
11. Boehringer Ingelheim Pharmaceuticals (2011) Boehringer Ingelheim Pharmaceuticals, Inc., Spiriva prescribing information. Available at: http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing+Information/PIs/Spiriva/Spiriva.pdf.
12. Brusasco V. Hodder R. Miravitlles M. Korducki L. Towse L. Kesten S. (2003) Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 58: 399–404.
13. Calverley P. Lee A. Towse L. van Noord J. Witek T. Kelsen S. (2003) Effect of tiotropium bromide on circadian variation in airflow limitation in chronic obstructive pulmonary disease. Thorax 58: 855–860.
14. Casaburi R. (2005) Factors determining constant work rate exercise tolerance in COPD and their role in dictating the minimal clinically important difference in response to interventions. COPD 2: 131–136.
15. Casaburi R. Mahler D. Jones P. Wanner A. San P. ZuWallack R. (2002) A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 19: 217–224.
16. Cazzola M. MacNee W. Martinez F. Rabe K. Franciosi L. Barnes P. (2008) Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 31: 416–469.
17. Chanez P. Burge P. Dahl R. Creemers J. Chuchalin A. Lamarca R. (2010) Aclidinium bromide provides long-acting bronchodilation in patients with COPD. Pulm Pharmacol Ther 23: 15–21.
18. Chrystyn H. Niederlaender C. (2012) The Genuair® inhaler: a novel, multidose dry powder inhaler. Int J Clin Pract 66: 309–317.
19. D–Urzo A. Make B. Kerwin E. Rekeda L. Sanz M. Caracta C. (2011) Safety and tolerability of twice-daily aclidinium bromide in COPD patients: ACCORD COPD I [poster]. In: Proceedings of the American Thoracic Society International Conference, 13–18 May 2011, Denver, CO.
20. De la Motte S. Beier J. Schmid K. Pascual S. Jansat J. Garcia Gil E. (2012) Pharmacokinetics and safety of aclidinium bromide in younger and elderly patients with chronic obstructive pulmonary disease. Int J Clin Pharmacol Ther, 50: 403–412.
21. Disse B. Reichl R. Speck G. Traunecker W. Rominger K. Hammer R. (1993) Ba 679 BR, a novel long-acting anticholinergic bronchodilator. Life Sci 52: 537–544.
22. Dolovich M. Ahrens R. Hess D. Anderson P. Dhand R. Rau J. (2005) Device selection and outcomes of aerosol therapy: Evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest 127: 335–371.
23. Fuhr R. Magnussen H. Sarem K. Ribera Llovera A. Kirsten A. Falques M. (2012) Efficacy of aclidinium bromide 400 microgram twice daily compared with placebo and tiotropium in patients with moderate to severe COPD. Chest 141: 745–752.
24. Fuhr R. Magnussen H. Singh D. De Miquel G. Caracta C. Garcia Gil E. (2011) Patient assessments of ease of use of Genuair® versus Aerolizer® and HandiHaler® [poster]. In: Proceedings of the European Respiratory Society Annual Congress, 24–28 September 2011, Amsterdam, the Netherlands.
25. Gavalda A. Miralpeix M. Ramos I. Otal R. Carreño C. Viñals M. (2009) Characterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profile. J Pharmacol Exp Ther 331: 740–751.
26. Gras J. Gavalda A. Llenas J. (2008) The preclinical cardiovascular safety profile of aclidinium bromide, a novel long-acting anticholinergic drug [poster]. In: Proceedings of the American Thoracic Society International Conference, 16–21 May 2008, Toronto, Canada.
27. Gross N. Skorodin M. (1984) Role of the parasympathetic system in airway obstruction due to emphysema. N Engl J Med 311: 421–425.
28. Halpin D. Miravitlles M. (2006) Chronic obstructive pulmonary disease: the disease and its burden to society. Proc Am Thorac Soc 3: 619–623.
29. Hass C. Engdahl K. Albert W. Setyawan J. Mateo N. (2010) Patient preferences and perceived ease of use in inhaler features: Genuair® vs other inhalers [poster]. In: Proceedings of the American College of Chest Physicians Annual Congress, 30 October–4 November, 2010, Vancouver, BC, Canada.
30. Holguin F. Folch E. Redd S. Mannino D. (2005) Comorbidity and mortality in COPD-related hospitalizations in the United States, 1979 to 2001. Chest 128: 2005–2011.
31. Jansat J. Lamarca R. de Miquel G. Schrödter A. Miletzki B. Gurniak M. (2009a) Safety and pharmacokinetics of multiple doses of aclidinium bromide, a novel long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease, in healthy participants. J Clin Pharmacol 49: 1239–1246.
32. Jansat J. Lamarca R. Garcia Gil E. Ferrer P. (2009b) Safety and pharmacokinetics of single doses of aclidinium bromide, a novel long-acting, inhaled antimuscarinic, in healthy subjects. Int J Clin Pharmacol Ther 47: 460–468.
33. Jones P. (2005) St. George's Respiratory Questionnaire: MCID. COPD 2: 75–79.
34. Jones P. Quirk F. Baveystock C. Littlejohns P. (1992) A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis 145: 1321–1327.
35. Jones P. Rennard S. Agusti A. Chanez P. Magnussen H. Fabbri L. (2011) Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease. Respir Res 12: 55.
36. Jones P. Singh D. Bateman E. Agusti A. Lamarca R. de Miquel G. (2012) Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study. Eur Respir J 40: 830–836.
37. Kerwin E. D–Urzo A. Gelb A. Lakkis H. Garcia Gil E. Caracta C. (2012) Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD 9: 90–101.
38. Kessler R. Partridge M. Miravitlles M. Cazzola M. Vogelmeier C. Leynaud D. (2011) Symptom variability in patients with severe COPD: a pan-European cross-sectional study. Eur Respir J 37: 264–272.
39. Kesten S. Jara M. Wentworth C. Lanes S. (2006) Pooled clinical trial analysis of tiotropium safety. Chest 130: 1695–1703.
40. Kochanek K. Xu J. Murphy S. Minino A. Kung H. (2011) Deaths: Preliminary Data for 2009. National Vital Statistics Rep 59(4): 1–51. Available at: http://www.cdc.gov/nchs/data/nvsr/nvsr59/nvsr59_04.pdf.
41. Lasseter K. Dilzer S. Jansat J. Garcia Gil E. Caracta C. Ortiz S. (2012) Safety and pharmacokinetics of multiple doses of aclidinium bromide administered twice daily in healthy volunteers. Pulm Pharmacol Ther 25: 193–199.
42. Lasseter K. Aubets J. Chuecos F. Gil E. (2011) Aclidinium bromide, a long-acting antimuscarinic, does not affect QT interval in healthy subjects. J Clin Pharmacol 51: 923–932.
43. Magnussen H. Watz H. Zimmermann I. Macht S. Greguletz R. Falques M. (2009) Peak inspiratory flow through the Genuair® inhaler in patients with moderate or severe COPD. Respir Med 103: 1832–1837.
44. Mahler D. Weinberg D. Wells C. Feinstein A. (1984) The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 85: 751–758.
45. Mahler D. Witek T. Jr (2005) The MCID of the transition dyspnea index is a total score of one unit. COPD 2: 99–103.
46. Make B. (2003) Chronic obstructive pulmonary disease: developing comprehensive management. Respir Care 48: 1225–1234; discussion 1234–1227.
47. Maltais F. Celli B. Casaburi R. Porszasz J. Jarreta D. Seoane B. (2011) Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD. Respir Med 105: 580–587.
48. Maltais F. Hamilton A. Marciniuk D. Hernandez P. Sciurba F. Richter K. (2005) Improvements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPD. Chest 128: 1168–1178.
49. Newman S. Sutton D. Segarra R. Lamarca R. de Miquel G. (2009) Lung deposition of aclidinium bromide from Genuair, a multidose dry powder inhaler. Respiration 78: 322–328.
50. O–Donnell D. Aaron S. Bourbeau J. Hernandez P. Marciniuk D. Balter M. (2007) Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2007 update. Can Respir J 14(Suppl. B): 5B–32B.
51. O–Donnell D. Flüge T. Gerken F. Hamilton A. Webb K. Aguilaniu B. (2004) Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 23: 832–840.
52. O–Donnell D. Guenette J. Maltais F. Webb K. (2012) Decline of resting inspiratory capacity in COPD: The impact on breathing pattern, dyspnea and ventilatory capacity during exercise. Chest 141: 753–762.
53. Ofir D. Laveneziana P. Webb K. Lam Y. O–Donnell D. (2008) Mechanisms of dyspnea during cycle exercise in symptomatic patients with GOLD stage I chronic obstructive pulmonary disease. Am J Respir Crit Care Med 177: 622–629.
54. Oga T. Nishimura K. Tsukino M. Sato S. Hajiro T. (2003) Analysis of the factors related to mortality in chronic obstructive pulmonary disease: role of exercise capacity and health status. Am J Respir Crit Care Med 167: 544–549.
55. Ortiz S. Flach S. Caracta C. Garcia Gil E. Jansat J. (2012) Safety and tolerability of aclidinium administered intravenously and absolute bioavailability of inhaled aclidinium in healthy male participants. J Clin Pharmacol 52: 819–827.
56. Partridge M. (2011) The burden of morning symptoms: the unrecognized unmet need in chronic obstructive pulmonary disease. Hot Topics Respir Med 6: 7–10.
57. Partridge M. Karlsson N. Small I. (2009a) Patient insight into the impact of chronic obstructive pulmonary disease in the morning: an internet survey. Curr Med Res Opin 25: 2043–2048.
58. Partridge M. Schuermann W. Beckman O. Persson T. Polanowski T. (2009b) Effect on lung function and morning activities of budesonide/formoterol versus salmeterol/fluticasone in patients with COPD. Ther Adv Respir Dis 3: 1–11.
59. Rennard S. (2011) COPD heterogeneity: what this will mean in practice. Respir Care 56: 1181–1187.
60. Rennard S. Tashkin D. McElhattan J. Goldman M. Ramachandran S. Martin U. (2009) Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial. Drugs 69: 549–565.
61. Schmid K. Pascual S. Gil E. Ortiz S. Jansat J. (2010) Pharmacokinetics and safety of aclidinium bromide, a muscarinic antagonist, in adults with normal or impaired renal function: A phase I, open-label, single-dose clinical trial. Clin Ther 32: 1798–1812.
62. Sentellas S. Ramos I. Alberti J. Salva M. Anton F. Miralpeix M. (2010) Aclidinium bromide, a new, long-acting, inhaled muscarinic antagonist: in vitro plasma inactivation and pharmacological activity of its main metabolites. Eur J Pharm Sci 39: 283–290.
63. Singh D. Magnussen H. Kirsten A. Mindt S. Caracta C. Seoane B. (2012) A randomised placebo- and active-controlled dose-finding study of aclidinium bromide administered twice a day in COPD patients. Pulm Pharmacol Ther 25: 248–253.
64. Tashkin D. Fabbri L. (2010) Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents. Respir Res 11: 149.
65. Tashkin D. Rennard S. Martin P. Ramachandran S. Martin U. Silkoff P. (2008) Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial. Drugs 68: 1975–2000.
66. Turck D. Weber W. Sigmund R. Budde K. Neumayer H. Fritsche L. (2004) Pharmacokinetics of intravenous, single-dose tiotropium in subjects with different degrees of renal impairment. J Clin Pharmacol 44: 163–172.
67. Vestbo J. Hurd S. Agusti A. Jones P. Vogelmeier C. Anzueto A. (2012) Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease, GOLD executive summary. Am J Respir Crit Care Med, DOI: 10.1164/rccm.201204-0596PP.
68. Vincken W. van Noord J. Greefhorst A. Bantje T. Kesten S. Korducki L. (2002) Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J 19: 209–216.
69. WHO. (2008) The global burden of disease: 2004 update, World Health Organization. Available at: http://www.who.int/healthinfo/global_burden_disease/GBD_report_2004update_full.pdf.